The latest news, tips and insights from Pelago, home of CETSA
Attrition levels in drug discovery remain high, with almost 60% of candidate drugs failing during clinical development due to insufficient efficacy. These failures have costly consequences for pharmaceutical and biotech companies. As well as gaining no return on their...read more
The new Alpha CETSA® HT kits available from Perkin Elmer will enable customers to utilise the power of CETSA HT in their own laboratories. The first 5 kits will be released to coincide with SLAS Europe with further protein targets becoming available soon. For more...read more
What could you achieve with a novel tool that better predicts efficacy outcome in clinical development?
Around the world, millions of patients need new drugs for life-threatening and incurable diseases. Yet, only around 1 out of 10 candidate drugs are gaining approval to enter the market. One of the main causes of this poor rate of success is a lack of efficacy during...read more
On September 23, Pelago Bioscience host our very first Customer Forum in Boston, US. This forum will gather researchers from Commercial and Academic drug discovery laboratories to present and discuss recent progress in the use of CETSA. The meeting will include case...read more
Read about CETSA from a medicinal chemistry perspective written by Pelago employee Stina Lundgren. Click here to read the articleread more